阿帕替尼单药治疗化疗失败后晚期胃癌的疗效及不良反应观察

胡云龙

摘  要：目的  探讨阿帕替尼单药治疗化疗失败后晚期胃癌的疗效及不良反应。方法  选取泰安市肿瘤防治院2018年12月～2019年12月期间收治的68例化疗失败胃癌晚期患者为对象，采用随机数表法分组，分为观察组与对照组，对照组34例常规化疗治疗（5-氟尿嘧啶+奥沙利铂+亚叶酸钙联合治疗方案），观察组34例阿帕替尼单药治疗，对比治疗有效率以及不良反应。结果  观察组治疗有效率高于对照组，不良反应率低于对照组，差异显著（P<0.05）。结论  通过使用阿帕替尼对化疗失败的胃癌晚期患者进行治疗，疗效显著，安全可靠。

关键词：阿帕替尼;化疗失败;晚期胃癌;不良反应

中图分类号：R735.2    文献标识码：A    文章编号：1009-8011（2021）-7-0003-03

Abstract： Objective  To investigate the efficacy and adverse reactions of apatinib as a single agent in the treatment of advanced gastric cancer that has failed chemotherapy. Methods  From December 2018 to December 2019 in our hospital， 68 patients with advanced gastric cancer who failed chemotherapy were selected as subjects. They were grouped by random number table and divided into observation group and control group. The control group had 34 conventional chemotherapy treatments（5-fluorouracil） + Oxaliplatin + leucovorin combined treatment program）， 34 cases of apatinib single-drug treatment were observed， and the treatment efficiency and adverse reactions were compared. Results  The treatment control rate of the observation group was significantly higher than that of the control group， and the adverse reactions were significantly lower than that of the control group. The difference was significant（P<0.05）. Conclusion  The use of apatinib to treat patients with advanced gastric cancer who have failed chemotherapy has a significant curative effect and is safe and reliable.

Keywords： apatinib; chemotherapy failure; advanced gastric cancer; adverse reactions

胃癌的發病率占恶性肿瘤发病率的第五位，具有较高的病死率[1-2]。胃癌在早期不易被发现，临床症状表现多变，超过一半的患者在首次就诊之后就已经被确诊为胃癌进展期甚至晚期，在接受手术治疗的患者中仍然有50%左右的患者会出现复发或转移的情况[3-4]。晚期胃癌患者的治疗主要以化疗为主，很多患者在使用紫杉类、氟尿嘧啶类等药物治疗失败之后出现了无药可用的情况，治疗有效率仍然比较低。有研究[5]显示，阿帕替尼在治疗化疗失败的胃癌晚期患者具有比较广泛的应用前景。本文选取医院34例化疗失败的胃癌晚期患者作为研究对象，探讨阿帕替尼单药治疗化疗失败后晚期胃癌的疗效及不良反应观察。现将研究结果报道如下。

1  资料与方法

1.1  一般资料

选取2018年12月～2019年12月进入泰安市肿瘤防治院进行治疗的68例化疗失败的胃癌晚期患者作为研究对象，采用随机数表法分组，分为观察组与对照组进行治疗，其中对照组34例，观察组34例。……